Early Secondary Graft Failure After Complete Donor Chimerism with Autologous Recovery Following Haploidentical HSCT for Relapsed B-ALL.

Rene A Amadore, Lynn B Bonifacio
{"title":"Early Secondary Graft Failure After Complete Donor Chimerism with Autologous Recovery Following Haploidentical HSCT for Relapsed B-ALL.","authors":"Rene A Amadore, Lynn B Bonifacio","doi":"10.31547/bct-2026-026","DOIUrl":null,"url":null,"abstract":"<p><p>Secondary graft failure after initial donor engraftment is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT). We report a 47-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL) who underwent haploidentical sibling peripheral blood HSCT after second complete remission. Neutrophil engraftment occurred by Day +14 with platelet engraftment by Day +18. Beginning Day +22, recurrent fever with progressive cytopenias developed. Day +30 peripheral blood short tandem repeat (STR) analysis showed complete donor chimerism; however, cytomegalovirus (CMV) DNAemia increased to 3,736 IU/mL, prompting therapeutic valganciclovir. Bone marrow biopsy on Day +37 showed hypocellular marrow without residual disease, although bone marrow X/Y fluorescence in situ hybridization (FISH) demonstrated 100% XY signals despite a female donor, indicating graft loss. Septic shock developed on Day +48. Management included growth factors, temporary tacrolimus withdrawal, antibiotics, granulocyte infusions, and a stem cell boost on Day +62. Repeat peripheral blood chimerism by Day +95 showed complete recipient genotype, confirming secondary graft failure with autologous reconstitution. Follow-up through Day +183 confirmed sustained autologous hematopoiesis with no relapse or graft-versus-host disease (GVHD). This case highlights an uncommon transition from donor-type marrow failure to autologous recovery and underscores the importance of bone marrow-based chimerism monitoring in cytopenic post-transplant patients.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"9 3","pages":"131-136"},"PeriodicalIF":0.0000,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548094/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood cell therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31547/bct-2026-026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Secondary graft failure after initial donor engraftment is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT). We report a 47-year-old man with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL) who underwent haploidentical sibling peripheral blood HSCT after second complete remission. Neutrophil engraftment occurred by Day +14 with platelet engraftment by Day +18. Beginning Day +22, recurrent fever with progressive cytopenias developed. Day +30 peripheral blood short tandem repeat (STR) analysis showed complete donor chimerism; however, cytomegalovirus (CMV) DNAemia increased to 3,736 IU/mL, prompting therapeutic valganciclovir. Bone marrow biopsy on Day +37 showed hypocellular marrow without residual disease, although bone marrow X/Y fluorescence in situ hybridization (FISH) demonstrated 100% XY signals despite a female donor, indicating graft loss. Septic shock developed on Day +48. Management included growth factors, temporary tacrolimus withdrawal, antibiotics, granulocyte infusions, and a stem cell boost on Day +62. Repeat peripheral blood chimerism by Day +95 showed complete recipient genotype, confirming secondary graft failure with autologous reconstitution. Follow-up through Day +183 confirmed sustained autologous hematopoiesis with no relapse or graft-versus-host disease (GVHD). This case highlights an uncommon transition from donor-type marrow failure to autologous recovery and underscores the importance of bone marrow-based chimerism monitoring in cytopenic post-transplant patients.

单倍体同种HSCT治疗复发性B-ALL后供体完全嵌合和自体恢复后早期继发移植物衰竭。
初次供体移植后继发移植物衰竭是异体造血干细胞移植(HSCT)的罕见并发症。我们报告了一位47岁的费城染色体阴性b细胞急性淋巴细胞白血病(B-ALL)患者,在第二次完全缓解后接受了单倍同卵兄弟姐妹外周血造血干细胞移植。中性粒细胞在第14天植入,血小板在第18天植入。从第22天开始,出现复发性发热伴进行性细胞减少。Day +30外周血短串联重复(STR)分析显示供体嵌合完全;然而,巨细胞病毒(CMV)脱氧核糖核酸血症增加到3736 IU/mL,提示使用缬更昔洛韦治疗。第37天的骨髓活检显示骨髓细胞减少,无残留疾病,尽管骨髓X/Y荧光原位杂交(FISH)显示100%的XY信号,尽管是女性供体,表明移植物丢失。感染性休克发生于第48天。治疗包括生长因子、暂时停用他克莫司、抗生素、粒细胞输注和第62天干细胞增强。Day +95重复外周血嵌合显示完全受体基因型,证实继发性移植物失败伴有自体重建。随访至第183天,证实持续自体造血,无复发或移植物抗宿主病(GVHD)。该病例强调了从供体骨髓衰竭到自体恢复的罕见转变,并强调了在细胞减少移植后患者中监测骨髓嵌合的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书